Improvement of MASLD and MASH by suppression of hepatic N-acetyltransferase 10
Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are characterized by excessive triglyceride accumulation in the liver. However, due to an incomplete understanding of its pathogenesis, more efforts are needed to i...
Saved in:
Main Authors: | Yanying Yang (Author), Jie Lu (Author), Yuejun Liu (Author), Ni Zhang (Author), Yunchen Luo (Author), Mingyue Ma (Author), Zhixia Dong (Author), Shuo Zhang (Author), Ming-Hua Zheng (Author), Cheng-Chao Ruan (Author), Xinjian Wan (Author), Cheng Hu (Author), Yan Lu (Author), Xiaojing Ma (Author), Bing Zhou (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Suppression of hepatic ChREBP⍺-CYP2C50 axis-driven fatty acid oxidation sensitizes mice to diet-induced MASLD/MASH
by: Deqiang Zhang, et al.
Published: (2024) -
Diagnostik der Metabolischen Dysfunktion-assoziierten Steatohepatitis (MASH)
by: Hans-Holger Bleß, et al.
Published: (2024) -
Creating and Presenting Mash-up Stories in the English Language Classroom in Japan
by: Suzanne Kamata
Published: (2023) -
Emerging therapies for MASLD and their impact on plasma lipids
by: Madison Nguyen, et al.
Published: (2024) -
Nano-drug delivery systems (NDDS) in metabolic dysfunction-associated steatotic liver disease (MASLD): current status, prospects and challenges
by: Ying Yang, et al.
Published: (2024)